Literature DB >> 20206678

Protection against nasal colonization with Streptococcus pneumoniae by parenteral immunization with a DNA vaccine encoding PspA (Pneumococcal surface protein A).

Daniela M Ferreira1, Maria Leonor S Oliveira, Adriana T Moreno, Paulo L Ho, David E Briles, Eliane N Miyaji.   

Abstract

Pneumococcal surface protein A (PspA) is an important candidate for a cost-effective vaccine with broad coverage against Streptococcus pneumoniae. We have previously shown that intramuscular immunization with PspA as a DNA vaccine induces an immune response characterized by the induction of a balanced IgG1/IgG2a antibody response in BALB/c mice, which was able to efficiently mediate complement deposition onto intact bacteria and to induce protection against an intraperitoneal challenge. We now confirm the results in C57BL/6 mice and further show that the response induced by the DNA vaccine expressing PspA is able to mediate protection against colonization of the nasopharyngeal mucosa even though immunization was given parenterally. Moreover, a positive correlation was observed between IgG1 and the numbers of CFU recovered, whereas an inverse correlation was observed between nasal CFU levels and IgG2a. A positive correlation was also found for IgG1/IgG2a antibody ratios with CFU recovered from the nasopharynx. Therefore, reduction of nasal colonization was strongly associated with increased levels of serum IgG2a complement fixing antibody and low levels of IgG1 antibody which has much less complement fixing activity. Passive transfer of serum from animals immunized with the DNA vaccine expressing PspA was also able to reduce the fraction of mice with high density of colonization of the nasopharynx. Secretion of IFN-gamma, but not IL-17, was observed in splenocytes from mice immunized with the DNA vaccine. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20206678     DOI: 10.1016/j.micpath.2010.02.009

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  11 in total

1.  MicroRNA-155 is required for clearance of Streptococcus pneumoniae from the nasopharynx.

Authors:  Chris P Verschoor; Michael G Dorrington; Kyle E Novakowski; Julie Kaiser; Katherine Radford; Parameswaran Nair; Varun Anipindi; Charu Kaushic; Michael G Surette; Dawn M E Bowdish
Journal:  Infect Immun       Date:  2014-08-25       Impact factor: 3.441

2.  Th17-Mediated Cross Protection against Pneumococcal Carriage by Vaccination with a Variable Antigen.

Authors:  Kirsten Kuipers; Wouter S P Jong; Christa E van der Gaast-de Jongh; Diane Houben; Fred van Opzeeland; Elles Simonetti; Saskia van Selm; Ronald de Groot; Marije I Koenders; Taj Azarian; Elder Pupo; Peter van der Ley; Jeroen D Langereis; Aldert Zomer; Joen Luirink; Marien I de Jonge
Journal:  Infect Immun       Date:  2017-09-20       Impact factor: 3.441

3.  Evaluation of a vaccine formulation against Streptococcus pneumoniae based on choline-binding proteins.

Authors:  Eliane N Miyaji; Cintia F M Vadesilho; Maria Leonor S Oliveira; André Zelanis; David E Briles; Paulo L Ho
Journal:  Clin Vaccine Immunol       Date:  2014-12-17

4.  Controlled inflammatory responses in the lungs are associated with protection elicited by a pneumococcal surface protein A-based vaccine against a lethal respiratory challenge with Streptococcus pneumoniae in mice.

Authors:  Fernanda A Lima; Daniela M Ferreira; Adriana T Moreno; Patrícia C D Ferreira; Giovana M P Palma; Jorge M C Ferreira; Isaias Raw; Eliane N Miyaji; Paulo L Ho; Maria Leonor S Oliveira
Journal:  Clin Vaccine Immunol       Date:  2012-07-03

Review 5.  Panel 6: Vaccines.

Authors:  Stephen I Pelton; Melinda M Pettigrew; Stephen J Barenkamp; Fabrice Godfroid; Carlos G Grijalva; Amanda Leach; Janak Patel; Timothy F Murphy; Sanja Selak; Lauren O Bakaletz
Journal:  Otolaryngol Head Neck Surg       Date:  2013-04       Impact factor: 3.497

Review 6.  Serotype-independent pneumococcal vaccines.

Authors:  Eliane Namie Miyaji; Maria Leonor Sarno Oliveira; Eneas Carvalho; Paulo Lee Ho
Journal:  Cell Mol Life Sci       Date:  2012-12-27       Impact factor: 9.261

7.  Maternal immunization with pneumococcal surface protein A protects against pneumococcal infections among derived offspring.

Authors:  Masamitsu Kono; Muneki Hotomi; Susan K Hollingshead; David E Briles; Noboru Yamanaka
Journal:  PLoS One       Date:  2011-10-31       Impact factor: 3.240

Review 8.  Role of Streptococcus pneumoniae Proteins in Evasion of Complement-Mediated Immunity.

Authors:  Greiciely O Andre; Thiago R Converso; Walter R Politano; Lucio F C Ferraz; Marcelo L Ribeiro; Luciana C C Leite; Michelle Darrieux
Journal:  Front Microbiol       Date:  2017-02-20       Impact factor: 5.640

9.  Characterization of protective immune responses induced by pneumococcal surface protein A in fusion with pneumolysin derivatives.

Authors:  Cibelly Goulart; Thais Raquel da Silva; Dunia Rodriguez; Walter Rodrigo Politano; Luciana C C Leite; Michelle Darrieux
Journal:  PLoS One       Date:  2013-03-22       Impact factor: 3.240

10.  PspA family distribution, antimicrobial resistance and serotype of Streptococcus pneumoniae isolated from upper respiratory tract infections in Japan.

Authors:  Muneki Hotomi; Akihisa Togawa; Masamitsu Kono; Yorihiko Ikeda; Shin Takei; Susan K Hollingshead; David E Briles; Kenji Suzuki; Noboru Yamanaka
Journal:  PLoS One       Date:  2013-03-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.